Blood test monitoring during chemo before surgery for HER2-positive breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether a blood test (ctDNA) can help doctors monitor how well chemotherapy before surgery is working in women with HER2-positive breast cancer. It aims to see if changes in the blood can predict treatment success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- You have early-stage breast cancer that is HER2-positive and the tumor is larger than 2 cm.
- You have not had any previous treatment for breast cancer.
- You are healthy enough to do everyday activities without help (ECOG score 0-1).
- You have tumors that can be measured by scans like CT.
- You agree to give blood and tumor tissue samples for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This study tests a new blood test to see if it can find tiny bits of tumor DNA after chemotherapy. If you have a larger or higher-risk breast cancer and are getting chemotherapy before surgery, you may join. The test could help doctors know if your cancer is gone or if more treatment is needed.
This trial is testing whether monitoring ctDNA (genetic material from the tumor in your blood) can help guide treatment for HER2-positive breast cancer before surgery. It is for people with early-stage (Stage II or III) disease who have not yet started treatment.
This study looks at whether a blood test (ctDNA) can help predict how well breast cancer responds to chemotherapy before surgery. It focuses on people with HER2-positive or triple-negative breast cancer that has not spread far.
This study looks for tiny traces of cancer after treatment by testing blood for “ctDNA,” which is leftover cancer DNA. It includes people with HER2-positive early breast cancer who are getting chemotherapy before surgery to see if this blood test can detect signs of remaining disease.
This study checks whether a blood test that looks for “tumor DNA” (circulating tumor DNA) can help evaluate how well neoadjuvant chemotherapy worked for breast cancer. It may help doctors better understand treatment response after surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.